Zentiva S.A (SCD) Fair Value & Analysis
Healthcare · RO · Market cap 3.2B RON
Fair value as of: Jun 26, 2026
From 26 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from 6.04 RON to 6.11 RON (+1.2%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range 4.52 RON – 4.52 RON · fair‑value band 2.91 RON – 7.64 RON · the 4.52 RON price screens below the 6.11 RON fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Zentiva S.A (SCD) currently trades at 4.52 RON, while our model-based Fair Value estimate is 6.11 RON — implying the stock looks roughly 35.2% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Zentiva S.A generated revenue of 1.1B RON at a net margin of 20.7%. Revenue grew 1.9% year over year. It earns a return on equity of 16.8%. The stock trades on a trailing P/E of 11.6. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Zentiva S.A. engages in the production and marketing of preparations and medicines for human use in Romania and internationally. The company develops pharmaceutical products in various therapeutic areas, such as cardiovascular diseases, anti-inflammatory and pain-relieving medications, urologists, blood diseases, gastrointestinal and metabolic disorders, central nervous system, infections, respiratory systems, and other, as well as develops generic medicines. It also offers educational materials for healthcare professionals and patients. The company was formerly known as Sicomed S.A. and changed its name to Zentiva S.A. in January 2006. The company was founded in 1962 and is based in Bucharest, Romania. Zentiva S.A. is a subsidiary of Zentiva Group a.s.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Zentiva S.A reported revenue of 1.1B RON in FY2024 versus 558M RON in FY2020, a compound +18.9%/yr. Reported net income was 251M RON in FY2024, compounding +39.8%/yr from FY2020.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zentiva S.A (SCD) undervalued?
What is the fair value of SCD?
What is the quality score of SCD?
What is the revenue of Zentiva S.A (SCD)?
What is the net profit margin of SCD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.